Search results
Moderna and MSD share encouraging three-year data from trial of melanoma therapy
Clinical Trials Arena via Yahoo Finance· 7 hours agoPharmaceutical companies Moderna and Merck & Co (MSD) have announced positive results from the Phase...
Experimental mRNA vaccines gain steam with promising cancer trial results
Semafor via Yahoo News· 20 hours agoInsights from TIME, The Washington Post, MIT Technology Review The News Pharmaceutical giants...
Merck Reaches $1.3 Billion Deal for Eye-Drug Company EyeBio
The Wall Street Journal· 6 days agoMerck’s venture arm was an investor in EyeBio. EyeBio’s lead drug, Restoret, is in development to...
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
Zacks via Yahoo Finance· 1 day agopharmaceutical companies. It is designed to provide capital appreciation by thoroughly evaluating...
Merck nears $1.3 bln takeover of Eyebiotech- WSJ By Investing.com
Investing.com· 7 days agoMerck nears $1.3 bln takeover of Eyebiotech- WSJ
Merck to Buy Eye Drug Company Eyebiotech for Up to $3 Billion. It’s Doubling Down on Deals.
Barrons.com· 6 days agoThe pharmaceutical company agrees to buy eye drug company Eyebiotech for up to $3 billion as it...
Merck to Acquire EyeBio
Morningstar· 6 days agoMerck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today ...
Merck Reportedly Nearing $1.3B Acquisition Of EyeBio To Expand Eye-Care Market Presence - Merck & Co...
Benzinga· 6 days agoMerck & Co., Inc. MRK is reportedly on the verge of acquiring EyeBio, an eye drug company, for a sum...
FDA sets review date for Merck's KEYTRUDA in mesothelioma treatment By Investing.com
Investing.com· 6 days agoMerck & Co., Inc., a global healthcare leader, has announced that the U.S. Food and Drug...
Merck to buy eye drug developer for $1.3B
BioPharma Dive via Yahoo Finance· 6 days agoAn acquisition of EyeBio will hand Merck a treatment for diabetic macular edema and age-related macular degeneration that’s ready for pivotal testing.
